Fortress Biotech reports Q3 EPS (8c), consensus (27c)

Reports Q3 revenue $16.53M, consensus $20.83M. Lindsay A. Rosenwald, Fortress’ chairman, president and CEO, said, "Fortress’ unique business model continues to provide value-creating events for our shareholders with a 17.5% net revenue increase for the first nine months of 2022, compared to the first nine months of 2021. We, along with our partner companies and subsidiaries, are focused on successfully advancing our 20 clinical-stage programs in 31 ongoing clinical trials, including seven1 pivotal clinical trials. Additionally, we have eight marketed dermatology products in our portfolio."